Overview
- The Chainalysis report published June 4, 2026 found first-quarter on-chain sales to identified peptide vendors reached $32 million, a 159% jump from Q4 2025 that puts the market on a greater-than-$100 million annual run rate.
- Vendors moved to cryptocurrency because banks and card processors often block payments tied to prescription-grade or unregulated compounds, making crypto the main payments rail for cross-border peptide sales.
- Chainalysis found that suppliers receiving average deposits of $1,000 or more now take most payments in stablecoins, a change that helps sellers avoid crypto price swings during large wholesale orders.
- Spending on independent product-purity testing per buyer fell about 88% to roughly $8, a collapse that means many new buyers are skipping lab verification and increases the risk of contaminated or mislabeled injectable products.
- On-chain tracing links much of the supply to Chinese chemical firms, including Shanghai Sigma Audley and Bigreat Technology, that previously sold drug precursors and now sell unbranded peptides direct to consumers, raising supply-chain and regulatory concerns.